

Curriculum Vitae

Date Prepared: March 22, 2019

Name: Taeseung Lee, M.D., Ph.D., RPVI.

Office Address: 166 Gumi-ro, Bundang-gu, Seonam-si, Gyeonggi-do

Home Address: Hansol APT 101-1403 Samsung dong Kangnam-gu
Seoul, South Korea

Resident registration number 620705-1023818

Work Phone: (031)787-7092

Work E-mail: tslee@snuh.org

Work FAX: (031)787-4078

Education:

March 1, 1984 – February 26, 1988	Doctor of Medicine, Seoul National University
March 1, 1991 – February 26, 1993	Master of Science in Medicine, Seoul National University
March 1, 1997 – February 26, 1999	Ph.D. in Medical Science, Seoul National University

Postdoctoral Training:

Internship and Residencies:

March 1, 1988 – February 28, 1989	Intern, Seoul National University Hospital
March 1, 1989 – January 31, 1993	General Surgery Resident, Seoul National University Hospital
February 1, 1993 – April 30, 1996	Army Doctor, Military Service
May 1, 1996 – February 28, 1997	Vascular Surgery Fellow, Samsung Medical Center
Mach 1, 1997 – February 28, 1998	Vascular & Transplantation Surgery Fellow, Seoul National University Hospital

Research Fellowships:

March 1, 1998 – August 31, 1998 Heart institute, Seoul National University College of Medicine

Study abroad:

September 1, 2000 ~ February 28, 2003, Postdoctoral fellowship, Section of Vascular Surgery, Yale University School of Medicine

September 1, 2006 ~ October 31, 2006, Visiting Surgeon, Section of Vascular Surgery University Pittsburgh Medical Center

August 1, 2010 ~October 1, 2010 Asia Pacific endovascular fellowship, Epworth Hospital. Melbourne, Australia

Faculty Academic Appointments:

September 1, 1998 – August 31, 2000 Instructor, Department of Surgery, Ajou University School of Medicine

March 1, 2003 – March 31, 2009 Assistant Professor of Surgery, Seoul National University College of Medicine

April 1, 2009- Associate Professor of Surgery, Seoul National University College of Medicine

Jan 1, 2014 ~ Professor of Surgery, Seoul National University College of Medicine

Appointments at Hospitals/Affiliated Institutions:

March 1, 2003 – Seoul National University Bundang Hospital, Seongnam-si

Major Administrative Leadership Positions:

2003 ~2005 Administrative Director, Department of Surgery Seoul National University Bundang Hospital

2014 ~ Director of organ transplantation center

July 1, 2016 ~ Chairman, Department of Surgery, Seoul National University Bundang Hospital

Professional Societies:

2018, 11 ~ Chairman of Boards, Korean society for vascular surgery

2015, 11~ Board member, Korean society for transplantation surgery

2012, 12~ 2016, 11 Publication committee chair, KSVS

2010, 12 ~2012, 12 Planning committee chair, KSVS

2013,1~2016, 12 Publication committee chair, KSVS

2009 Secretary General, The 10th Asian Society for Vascular Surgery
 2006, 12 –2010, 12 Secretary, Korean Society for Vascular Surgery
 1998 – Member, Korean Society for Transplantation Surgery
 1998 – Member, Korean Society of Medical Biochemistry and Molecular Biology

Honors and Prizes:

2003 Outstanding paper award, The Korean Federation of Science and Technologies
 2007 The 1st LeeYongkak- Astellas Clinical Research Award
 2011 The 1st LeeYongkak- Astellas Basic Research Award

Report of Funded Projects

2003, 12-2011, 6	Principal Investigator	Seoul National University Bundang Hospital	\$10,000
버거씨 질환의 병인 규명을 위한 기초연구			
2004, 7-2012, 12	Principal Investigator	Seoul National University Bundang Hospital	\$20,000
버거씨 질환의 병인 규명을 위한 기초연구 (버거씨병 환자 및 흡연자 그리고 비흡연자에서 추출한 내피전구세포의 특성분석)			
2005, 7-2012, 6	Principal Investigator	Seoul National University Bundang Hospital	\$10,000
전단응력에 노출된 내피전구세포의 활성화 분석			
2006, 6-2008, 7	Principal Investigator	Korean Research fund	\$45,000
The effect of Cell therapy for vascular disease animal models.			
2008 – 2010	Co-Investigator	Ministry Knowledge Economy	\$250,000
Development of small & medium sized artificial blood vessels			
2008, 2-2012, 5	Co- Investigator	LSK Global PS	\$600
직접 트롬빈 억제제(Direct thrombin inhibitor)인 다비가트란 이택실레이트의 하루 두번 경구 복용이 심부 정맥 혈전증(deep vein thrombosis)이나 폐색전증(pulmonary embolism) 환자들의 재발성 증후성 정맥 혈전 색전증을 장기간 예방할 수 있는지에 대한 연구			
2008 – 2011	Co-Investigator	Korea Science and Engineering Foundation	\$100,000
Development of experimental chronic lymphedema model and comprehensive approach of lymphangiogenesis			

2009,8 - 2011-8	Co-Investigator	IQVIA	\$71,520
급성 중후성 정맥 혈전색전증에 대해 승인된 비경구적 항응고제로 초기에 5 일 이상 치료한 후 6 개월 동안 투여된 경구용 Dabigatran Etexilate(150mg 1 일 2 회)의 유효성 및 안전성을 와파린(INR 2.0-3.0)과 비교하여 평가하기 위한 제 3 상 무작위배정, 이중맹검, 평행군 임상시험. RE-COVER II			
2010,5 - 2014, 3	Co-Investigator	IQVIA	\$166,737
증상을 동반한 심부정맥 혈전증 및 혹은 폐색전증이 있는 피험자를 대상으로한 저분자량 헤파린/와파린대비 저분자량 헤파린/Edoxaban 의 유효성과 안전성 평가를 위한 제 3 상, 무작위배정, 이중 눈가림, 이중 위약, 평행군, 다기관, 다국가 연구			
2013, 1 - 2015, 8	Co-investigator	astellas	\$8,800
Validation of the Korean version of the Walking Impairment Questionnaire in patients with peripheral arterial disease			
2013,12-2018,12	Co- Investigator	Seoul National University Hospital	\$7,920
급성 장골-대퇴정맥 혈전증 환자에서 혈전용해술 후 rivaroxaban 의 재발에 대한 효과 및 안전성 분석			
2014,6 - 2018, 11	Principal Investigator	Seoul National University Bundang Hospital	\$17,600
Enhancing survival of bone marrow derived mesenchymal stem cells by use of self-assembling peptides			
2015, 12 – 2020, 3	Co-Investigator	Bayer	\$133,000
하지 혈관재개통술을 받은 증상성 말초동맥질환 환자들에서 주요 혈전성 혈관 사건의 위험을 감소시키는 리바록사반의 유효성 및 안전성을 연구하는 국제, 다기관, 무작위배정, 이중눈가림, 위약대조 제 3 상 임상시험			
2015 ,12 – 2018 ,11	Co-Investigator	Seoul National University Bundang Hospital	\$17,600
Effects of bone marrow mesenchymal stem cells and self-assembling Bio peptides in a murine hindlimb ischemia model with insights into its mechanism of action			
2016, 6 – 2018, 11	Principal Investigator	Seoul National University Bundang Hospital	\$17,600
Role of mesenchymal stem cell-recruiting self-assembling bio peptide in improving capillary inosculation after graft implantation in a diabetic foot ulcer rat model			
2017, 7 – 2020, 1	Co-Investigator	Daewoong	\$30,370
말초동맥혈관질환에서 경피적혈관성형술 후 Clopitogrel 과 Aspirin 의 투여와 비교하여 Anplone 과 Aspirin 의 이중 항혈소판제의 6 개월 투여 후 유효성과 안전성 비교			

Certification / Licensure

1. Korean Medical Association(MD) #36043
2. Certified, Korean Board of Surgery #3132
- 3, Certified, ARDMS RPVI #120262

Patent

CTRP3 (10-2017-0096257)
Malesin1 (10-2007-0022466)
Protectin (10-2017-0022465)

Presentation

1. Treatment of aortoiliac occlusive disease. 3th Congress of the Asian Vascular Society, Beijing, China, May, 1998
2. Combined iliac balloon angioplasty and distal surgical revascularization. 3th Congress of the Asian Vascular Society, Beijing, China, May, 1998
3. Morphologic change of internal elastic lamina in Buerger's disease. 3th Congress of the Asian Vascular Society, Beijing, China, May, 1998
4. The pathobiology of intimal hyperplasia. Surgical Grand Round, Seoul National University, Seoul, Korea, Sep, 1998
5. The pathobiologic study of Buerger's disease. The 1st Japan-Korea Joint Meeting for Vascular Surgery, Omiya Sonic City, Japan, May, 1999
6. Expression of cell cycle regulatory factors after balloon catheter arterial injury in rats. The 1st Japan-Korea Joint Meeting for Vascular Surgery, Omiya Sonic City, Japan, May, 1999
7. Immune tolerance induction by depleting anti-CD4 antibody in heterotopic heart allograft of rat model. The 30th annual congress of the Korean Society of Transplantation, Seoul, Korea, Oct, 1999
8. The C terminal domain of thrombospondin-1 induces VSMC chemotaxis through ERK1/2 and p38. The 35th Association for Academic Surgeon, Milwaukee, USA, Nov, 2001.
9. Thrombospondin-1 induces matrix metalloproteinase 2 activation in vascular smooth muscle cells. The 16th Eastern vascular society meeting, Boston, USA, May, 2002.
10. Cartilage oligomeric matrix proteins is protective against apoptosis. The 57th Society for Vascular surgery/ 51th American Association for Vascular Surgery (Vascular annual meeting 2003), McCormick place Chicago, IL, June 2003
11. The role of thrombospondin-1 in human disease. Surgical Grand Round, Seoul National University, Seoul, Korea, June, 2003
12. Nicotine induced angiogenic potential in human umbilical vein endothelial cell. 5th Congress of the Asian Vascular Society, Bangalor, India, April, 2004
13. Controversial issues for deep vein thrombosis management. Surgical Grand Round, Seoul National University, Seoul, Korea, 2004
14. Recent advances in vascular surgery. Surgical Grand Round, Seoul National University, Seoul, Korea, April, 2005
15. Less invasive aorta surgery. Surgical Grand Round, Samsung Medical center, Seoul, Korea, October, 2005
16. Laparoscopic aorta surgery. The 34th Annual meeting of Japanese Society for Vascular Surgery, Tokyo, 2006

17. Management of Primary Varicose Vein. The 26th Annual meeting of Japanese Society for Phlebology Meeting, Asasikawa, June 2006
18. Minimal invasive aorta surgery. The 3rd internation endovascular & laparoscopic congress. New York, NY, Nov 2006
19. Decreased number and impaired functions of endothelial progenitor cells in patients with thromboangiitis obliterans. The 35th Annual meeting of Japanese Society for Vascular Surgery, Nagoya, 2007
20. The quality of life after varicose vein surgery. The 28th Annual meeting of Japanese Society for Phlebology Meeting, Hakone, 2008.
21. Overview on modern treatment of varicose vein. The 10th Asian Society for Vascular Surgery. Busan, South Korea, 2009.
22. Endothelial differentiation of muscle derived stem cell by shear stress & VEGF application. The 10th Asian Society for Vascular Surgery. Busan, South Korea, 2009.
23. Endovascular treatment for the PAD patient with DM. The 11th Asian Society for Vascular Surgery. Kyoto, Japan, 2010 July 1.
24. Differentiated MDSC attenuate intimal hyperplasia after carotid balloon injury in rat. The 11th Asian Society for Vascular Surgery. Kyoto, Japan, 2010 July.
25. Laparoscopic aortofemoral bypass. KOSIS, Seoul Nov 18, 2010.
26. Laparoscopic aorta surgery. Surgical Grand Round, Seoul National University, March 26, 2011
27. Perspective Laparoscopic vascular surgery. Laparoscopic surgery update 2011, Seongnam city, July, 2011.
28. Carotid endarterectomy stand still over CAS. Encore Seoul 2011, Seoul
29. Initial EVAR experiences with consecutive 50 patients: short term complication. Endovascology 2011, Shanghai, China.
30. Quality of life after varicose vein surgery: Prospective, nonrandomized study. VENUS expert forum. 2012 March 24 Seoul, Korea
31. Management for various complication during varicose vein surgery. The spring congress of Korean Society of Phlebology, March 25, 2012
32. Lessons from initial EVAR experiences. SGR, Seoul National University. March 24, 2012
33. Why hybrid OR is necessary? VIS meeting, April 14, 2012, Seoul Korea
34. Total laparoscopic AAA repair. Laparoscopic surgery update 2012, Seongnam city, June 6, 2012.
35. Proposal for the prevention of VTE in HBP, UGIS, and colorectal cancer surgery. The fall congress of The hemostasis and thrombosis Korean society meeting, OCT 12, 2012 Seoul National University Lee Kunhee hall.
36. Symptomatic spontaneous celiac artery dissection. Endovascology Oct 20, 2012, Shanghai, China.
37. Case presentation of vascular disease. The Korean Surgical Ultrasound Society 2012 December 9, Auditorium Samsung, Medical Center.
38. Uniform reporting standards after endovascular treatment for leg atherosclerosis. SNU Bi-vascular symposium Feb 23, 2013.
39. Surgery vs. endovascular therapy for challenging aortic aneurysm. The Japan-Korea joint meeting /57th KSVS spring congress. Seoul Jamsil Lotte Hotel 2013, April 27
40. Minimal invasive aortic aneurysm surgery. The 8th international postgraduate course of laparoscopic surgery. Seoul National University Bundang Hospital. 2013 June 15
41. Laparoscopic surgery of AAA. Samsung Vascular Symposium. June 2013
42. Future surgery. Surgery summer workshop for student. July, 2013

42. Tailored approach to femoral artery (SFA) disease. SGR. 2013, Seoul. Korea.
43. Atherosclerosis: General considerations and management of risk factors. KSVS PG courses. 2013: Oct 19.
44. Endovascular treatment of DVT. The Congress of Korean society of lymphedema. Nov 16, 2013
45. Experimental AAA formation and potential role of VSMCs progenitor cell therapy. The fall congress of KSVS. Nov 2013.
46. Recent advances in AAA research. SNU Bi-vascular symposium Feb 22, 2014.
47. Hybrid repair of AAA. ICON 2014 Arizona Phoenix. Feb 2014
48. The future of Korean society for vascular surgery. KSVS 30TH anniversary meeting 2014 April.
49. BTK angioplasty in Diabetic ischemic foot ulcer. SGR 2014 July
50. The chronological change of aneurysm sac after EVAR. ASVS 2014 Hongkong. 2014: September
51. The early diagnosis and treatment of vascular disease. Broad symposium Seoul. 2014 Oct 27.
52. How to use valvulome in situ bypass. VESSEL 2014 Dec 6.
53. Treatment of isolated iliac artery aneurysm SNU Bi-vascular symposium Feb 28, 2015.
54. CERAB or LAP AFB. SNU Bi-vascular symposium Feb 28, 2015.
55. Post EVAR surveillance. KSVS spring annual meeting 2015 April.
56. Hybrid OR, what for?. SNUBH anesthesiology morning conference. 2015 April 29.
57. Technical considerations for optimal outcomes after treatment of isolated iliac artery aneurysms. The 9th Japan-Korea joint meeting for vascular surgery. Pacifico Yokohama June 5, 2015
58. Vascular system and surgical approach to vascular disease. SNUBH nurse education, August 26, 2015
59. Proper treatment of isolated iliac artery aneurysm and its future direction. SGR August 28, 2015
60. Failure of open repair in ruptured AAA. G-ALIVE symposium. Oct 31, 2015
61. The interpretation of vascular lab for nurse. SNUBH nurse education, Feb 20, 2015
62. In situ bypass with minimal incisions. SBiS Feb 27, 2016
63. Endo vs Open: How to decide an optimal treatment strategy? Samsung Vascular meeting May 2016
- 64 Team approach for DMF management. Ulsan University surgical conference, June 2016
65. Team approach for DMF. Korean wound society education symposium. Sep 2016
- 65 Surgeon modified stent grafts. SGR Oct 19, 2016
66. How to overcome terrible situations during EVAR. SBiS Feb 2017
67. Hybrid surgery. COOK workshop. March 17, 2017
68. Sac enlargement with type 2 endoleak after EVAR: when and how to treat? Samsung Vascular symposium. May 2017.
69. Abdominal aortic aneurysm surgery. Severance postgraduate school. May 11, 2017.
70. Infected stent graft and aneurysm: incidence, risk factors and treatment options. Encore meeting Oct 2017
71. Early experience with physician modified stent grafts for endovascular treatment of hostile abdominal aortic aneurysms. SBiS Feb 19, 2018.
72. Open vs EVAR for ruptured abdominal aortic aneurysms – SNUBH experiences. SGR May, 2018
73. Beyond IFU EVAR for abdominal aortic aneurysm. Severance postgraduate school. May 11, 2018.

74. Outcomes of distal bypass for infrapopliteal artery occlusion in critical limb ischemia. ASVS July 14, 2018
75. Early experiences of physician modified endograft for AAA. LINK , 2019
76. Physician modified graft planning. SBiS 2019
77. The treatment of superficial femoral artery disease : 10 years' wandering journey with partners. C OOK workshop. 2019 March 1

Selected Publication Lists

1. Lee T, Park JG, Choe KJ, Kim JP. A clinical study of smooth muscle tumors arising from lower GI tracts. *K.C.P.S* 7(2):113-120, 1991.
2. Lee T, Kim SJ. The effect of cyclosporine and dexamethason on suppression of medial thickening in arterial injury in rats. *The Seoul Journal of Medicine* 34(4): 265-273, 1993.
3. Lee T, Jung IM, Yun IJ, Cho BS, Ha J, Kim TK, Park JH, Kim SJ. Fate of bypass grafts for renal reconstruction:angiographic findings. . *The Journal of Korean Vascular Surgery.* 13(2):193-197, 1997.
4. Lee T, Jung IM, Cho BS, Ha J, Kim SJ. The effect of ratio of kidney weight to recipient weight and body surface area on the renal allograft outcome. *The Journal of Korean transplantation Surgery,* 11(2):247-252, 1997.
5. Lee T, Won JH, Kim MW. Thrombolytic therapy in deep vein thrombosis. *The Journal of Korean Vascular Surgery.* 15(2):291-296, 1999.
6. Lee T, Jung IM, Seo JW, Jung MH, Kim SJ. Effects of Prostaglandin E₁ on the Oxidative Stress Injury Index and the Expression of PCNA in Vein Grafts of Rabbit Carotid Arteries. *The Journal of Korean Surgical Society* 58(2):1-8, 2000
7. Lee T, Bae KS, Kim MW. Nutcracker syndrome 2 cases. *The Journal of Korean Vascular Surgery* 16(2)245-248, 2000.
8. Lee T, Kim SJ, Sumpio BE. The role of PP2A in p38MAPK pathway in bovine aortic endothelial cells exposed to cyclic strain. *J cellular physiology* 194:349-355, 2003
9. Lee T, Seo JW, Sumpio BE, Kim SJ. The pathobiology in Buerger's disease. *European J of Vascular and Endovascular Surgery* 25(5):451-7, 2003
10. Lee T, Nesselroth SM, Olson ET, Esemuede N, Sumpio BE, Gahtan V. Thrombospondin-1 induces vascular smooth muscle cell chemotaxis: The role of type 3 repeat and carboxyl terminal doamins. *J Cellular Biochemistry* 89(3):500-6, 2003
11. Lee T, Esemuede N, Sumpio BE, Gahtan V. Thrombospondin-1 induces matrix metalloproteinase-2 activation in vascular smooth muscle cells. *J Vasc Surg* 38(1):147-54, 2003
12. Lee T, Ha Jongwon, Chung JK, Kim SJ. Treatment of vascular access induced ischemia with distal revascularization interval ligation. *The Journal of Korean Vascular Surgery.* 20(2):272-275, 2004
13. Lee T, Sumpio BE. Cell signalling in vascular cells exposed to cyclic strain: the emerging role of protein phosphatases. *Biotechnol Appl Biochem* 39(Pt 2):129-39, 2004
14. Lee T. Management of small AAA/ New attempt to prevent expansion or rupture of AAA. *The Journal of Korean Vascular Surgery.* 21(1):84-86, 2005
15. Lee T, Kim HH, Han HS, Choi YS, Lee SI, Ha JW, Chung JK, Kim SJ. Laparoscopic-assisted aortofemoral bypass. *The Journal of Korean Surgical Society* 69(3):269-272, 2005
16. Lee T. Intermittent claudication and Buerger's disease. *Diatreat in practice for physician.* 5(3): 1750-1752, 2005

17. Lee T. Less invasive aorta surgery. *Medical postgraduates* 33(6):363-368, 2005
18. Lee T. Total laparoscopic aortofemoral bypass. *The Journal of Korean Surgical Society* 72(4):332-335, 2007
19. Lee T. Limited feasibility in endovascular aneurysm repair using currently available graft in Korea. *J of Korean Medical Science*. 2008;23(4):651-656
20. Lee T. Two port laparoscopic placement of a peritoneal dialysis catheter with abdomen wall fixation. *Surgery Today*. 39:56-58, 2009
21. Lee T. Early experiences of laparoscopic aortofemoral bypass in Korea: report from a single center. *Ann Vasc Dis*. 2(1):34-39, 2009
22. Eom BW, Lee T, Kim HH, Han HS, Ha JW, Chung JK, Kim SJ. Robot assisted aortofemoral bypass. *J Korean Surg Soc* 2009;76(4):266-269
23. Jang MJ, Choi WI, Bang SM, Lee T, Kim YK, Ageo W, Oh D. Metabolic syndrome is associated with venous thromboembolism in the Korean population. *Arterio Thromb Vasc Biol*. 23:311-3, 2009
24. Yi JW, Jung IK, Lee TS, Min SK, Min SJ, Park YJ, Ha JW, Chung JK, Kim SJ. Acute arterial thromboembolism of upper extremity. *J Korean Surg Soc* 2010;79:491-496
25. Min SK, Kim SY, Park YJ, Lee W, Jung IM, Lee T, Ha J, Kim SJ. Role of three dimensional computed tomography venography as a powerful navigator for varicose vein surgery. *J Vasc Surg* 51:893-9, 2010
26. Jung IM, Han SR, Choi KH, Kwon Y, Lee TS, Min SK, Park YJ, Chung JK, Ha J, Kim SJ. Differentiated muscle derived stem cells attenuate intimal hyperplasia after carotid balloon injury in rat. *J Korean Surg Soc* 2010;79(06):S7-15.
27. Park HS, Lee TS, Yoon CJ, Kang SK, Min SK, Ha J, Chung JK, Kim SJ. Outcomes of endovascular intervention and bypass surgery for femoral artery atherosclerosis. *J Korean Surg Soc* 2010;79(03):215-222
28. Lippi G, Veith F, Sumpio B, Azuma N, Lee T, Parakh R, Bias G. Terms of reference for the standards of practice and training committee. *Vascular* 2010 Jul-Aug 18(4), 227-9.
29. Ahn KS, Han HS, Yoon YS, Kim HH, Lee TS, Kang SB, Cho JY. Laparoscopic resection of non-adrenal retroperitoneal tumors. *Arch Surg* 146(2):162-167, 2011
30. Willis AI, Sadowitz B, Fuse S, Maier KG, Lee TS, Wang XJ, Tuszynski GP, Sumpio BE, Gahtan V. Thrombospondin 1, fibronectin, and vitronectin are differentially dependent upon RAS, ERK1/2, and p38 for induction of vascular smooth muscle cell chemotaxis. *Vascular and endovascular surgery* 2011;45(1):5-62
31. Esemuede N, Lee T, Maier KG, Sumpio BE, Gahtan V. Lovastatin inhibits thrombospondin 1 induced smooth muscle cell chemotaxis. *J Sur Res*. 2011;168(1):149-54
32. Park HS, Cho K, Park YJ, Lee T. Chronic nicotine exposure attenuates proangiogenic activity on human umbilical vein endothelial cells. *J Cardiovasc pharmacol* 57(3):287-93, 2011
33. Hwang JH, Kim IG, Lee JY, Pias S, Lee DS, Lee TS, Ra JC, Lee JY. Therapeutic lymphangiogenesis using stem cell and VEGF-C hydrogel. *Biomaterials* 2011;32(19):4415-23
34. Lee T, Ra HD, Park YJ, Park HS, Kim SJ. New routing alternative for proximal anterior tibial artery bypass in patients with Buerger's disease *J Vasc Surg* 54:1839-41, 2011
35. Hyung Sub Park, Taeseung Lee, Sang Joon Kim. Letter to editor. *J Vasc Surg* 56(2);591 2012
36. Park HS, Hahn S, Choi GH, Yoo YS, Lee JY, Lee T. Muscle derived stem cells promote angiogenesis and attenuate intimal hyperplasia in different murine vascular disease models. *Stem cell Dev*. 2012;22(6):866-77

37. Park HS, Choi GH, Hahn SL, Yoo YS, Lee JY, Lee T. Potential Role of Vascular Smooth Muscle Cell like Progenitor Cell Therapy in the Suppression of Experimental Abdominal Aortic Aneurysms. *Biochem Biophys Res Commun* 2013;431(2):326-31
38. Park HS, Kwon YJ, Eom BW, Lee T. Prospective nonrandomized comparison of quality of life and recurrence between high ligation and stripping and radiofrequency ablation for varicose veins. *J Korean Surg Soc* 2013;84(1):48-56
39. The Houkusai-VTE investigators.
Edoxaban versus Warfarin for the treatment of symptomatic venous thromboembolism. *NEJM* 2013 Sep 13.
40. Park HS, Jung In Mok, Choi GH, Hahn SL, Yoo YS, Lee T. Modification of a rodent hindlimb model of secondary lymphedema: Surgical radicality versus radiotherapeutic ablation. *Biomed Research International* 2013;2013:1-10 article ID. 208912
41. Park HS, Cho KH, Lim KL, Kim DK, Lee T. Reduced circulating endothelial progenitor cells in thromboangiitis obliterans. *Vascular medicine* 2013;18(6):331-339
42. Park JY, Galimzahn A, Park HS, Yoo YS, Lee T. Midterm results of radiofrequency ablation for incompetent small saphenous vein in terms of recanalization and sural neuritis. *Dermatological surgery* 2014 April 40(4):383-9
43. Won SH, Lee T, Lee KM. Risk factors associated with amputation free survival in patients with Diabetic foot ulcer. *Yonsei Med J* 2014;55(5):1373-1378
44. Nam K, Seo JK, Lee T, Hwang JW. Randomized clinical trial on the preventive effects of butylscopolamine on early postoperative catheter-related bladder discomfort. *Surgery* 2015;157:396-401
45. Ahn S, Min SK, Min SI, Ha J, Lee T. Treatment strategy for persistent sciatic artery and novel classification reflecting anatomic status. *Eur J Vasc Endovasc Surg* 2016;52:360-369
46. Park HS, Han MY, Jung IM, Lee T. Role of laser Doppler for the evaluation of pedal microcirculatory function in diabetic neuropathy patients. *Microcirculation* 2016;23:44-52
47. Jung TW, Park HS, Choi GH, Kim DH, Lee T. CTRP9 regulates growth, differentiation, and apoptosis in human keratinocytes through TGF β -p38-dependent pathway. *Mol cells* 2017;40(12):906-915
48. Choi CH, Lee T, Min SK, Han AR, Kim SY, Min SI, Ha JW, Jung IM. Validation of the Korean version of the walking impairment questionnaire in patients with peripheral arterial disease. *Ann Surg Treat Res.* 2017;93(2):103-109
49. Jung TW, Park HS, Choi GW, Kim DW, Lee T. β -aminoisobutylic acid attenuates LPS-induced inflammation and insulin resistance in adipocytes through AMPK mediated pathway. *Journal of Biomedical science* 2018;28:25(1)

50. Jung TW, Park HS, Choi GW, Kim DW, Jeong JH, Lee T. Chitinase-3-like protein1 ameliorates atherosclerotic responses via PPAR γ -mediated suppression of inflammation and ER stress. *J Cell Biochem* 2018;119:6795-6805
51. Jung TW, Park HS, Choi GW, Kim DW, Ahn SH, Kim DS, Lee T, Jeong JH. Maresin1 attenuates pro-inflammatory reactions and ER stress in HUVECs via PPAR α -mediated pathway. *Molecular and cellular Biochemistry*. 2018;448:335-347
52. Park HS, Cho KH, Kim DW, Jung TW, Jung IM, Chung JK, Lee T. Use of self-assembling peptides to enhance stem cell function for therapeutic angiogenesis. *Stem cells International*. 2018;2018:4162075
53. Lee T, Y SB, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. *Molecular and cellular endocrinology*. 2019;486:96-104
54. K JW, Kim DW, Quan C, Suh YJ, Ann HY, Kim JI, Moon IS, Lee T. Treatment options for isolated iliac artery aneurysms and their impact on aortic diameter after treatment. *Ann Sur Treat Res*. 2019;96(3):146-151
55. Ko DY, Park HS, Kim JY, Kim DW, Lee T. Early experiences of endovascular aneurysm repair for ruptured abdominal aortic aneurysms. *Ann Sur Treat Res*. 2019;96(3):146-151
56. Ahmed E, Kim DW, Park HS, Lee T. Access site pseudoaneurysm after endovascular intervention for peripheral arterial disease. *Ann Surg Treat Res*. 2019 (accepted)

Book chapter

Abdominal aortic aneurysm, management of type 2 endoleak
 Atlas of Surgical procedure, high ligation and stripping of varicose vein
 Textbook of Surgery, lymph physiology & lymphedema
 Lymphedema: The comprehensive guide for practitioners
 Vascular access for hemodialysis

Narrative Report

I currently serve as a chief of Vascular surgery division in Seoul National University Bundang Hospital. The main clinical interests are the minimal invasive aorta surgery through laparoscopic/robotic or endovascular repair for early recovery of those sick patients and aggressive foot salvage for Diabetic foot wound. My basic research efforts broadly aims at delineating the pathogenesis of developing and growing aneurysm and control. Also, I am also interested in stem cell research for treatment of swollen leg and cold leg.